tbuckley/cabot-search huggingface dataset:
Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations
Authors: Daniel Sanghoon Shin, Jesse M. Zaretsky, Helena Escuin-Ordinas, Angel Garcia-Diaz, Siwen Hu-Lieskovan, Anusha Kalbasi, Catherine S. Grasso, Willy Hugo, Salemiz Sandoval, Davis Y. Torrejon, Nicolaos Palaskas, Gabriel Abril Rodriguez, Giulia Parisi, Ariel Azhdam, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Beata Berent-Maoz, I. Peter Shintaku, Dung T. Le, Drew M. Pardoll, Luis A. Diaz, Paul C. Tumeh, Thomas G. Graeber, Roger S. Lo, Begoña Comin-Anduix, Antoni Ribas
Journal: Cancer Discovery (2016)

Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti-PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 patients with mismatch repair-deficient colon cancer treated with PD-1 blockade. Both cases had a high mutational load but did not respond to anti-PD-1 therapy. Two out of 48 human melanoma cell lines had JAK1/2 mutations, which led to a lack of PD-L1 expression upon interferon gamma exposure mediated by an inability to signal through the interferon gamma receptor pathway. JAK1/2 loss-of-function alterations in The Cancer Genome Atlas confer adverse outcomes in patients. We propose that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188-201. ©2016 AACR.See related commentary by Marabelle et al., p. 128This article is highlighted in the In This Issue feature, p. 115.
Acquision of Resistance to Doxorubicin By Breast Cancer Cells MCF7 Enhances Their Procoagulant Properties and Alters the Efficacy of Antithrombotic Agents to Inhibit Thrombin Generation
Authors: Aurélie Rousseau, Patrick Van Dreden, Amir Khaterchi, Elisabeth Mbemba, Annette Larsen, Ismail Elalamy, Grigorios T. Gerotziafas
Journal: Blood (2015)
ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
Authors: Timothy P. Hughes, Andreas Hochhaus, Giuseppe Saglio, Dong-Wook Kim, Saengsuree Jootar, Philipp D. le Coutre, Josy Reiffers, Ricardo Pasquini, Clarisse Lobo, Richard E. Clark, Neil J. Gallagher, Albert Hoenekopp, Ariful Haque, Richard A. Larson, Hagop M. Kantarjian
Journal: Blood (2010)
Carbohydrate Estimation Supported by the GoCARB System in Individuals With Type 1 Diabetes: A Randomized Prospective Pilot Study
Authors: Lia Bally, Joachim Dehais, Christos T. Nakas, Marios Anthimopoulos, Markus Laimer, Daniel Rhyner, George Rosenberg, Thomas Zueger, Peter Diem, Stavroula Mougiakakou, Christoph Stettler
Journal: Diabetes Care (2016)

Accurate carbohydrate (CHO) counting to achieve satisfactory glucose control in type 1 diabetes (T1D) remains challenging in practice, and thus novel approaches are still needed (1,2). GoCARB is a computer vision-based application installed in a smartphone device that provides users with CHO content estimations from photos taken of plated meals (3). We present the results of a pilot prospective randomized controlled crossover study (NCT02546063) evaluating the effects of GoCARB on postprandial and overall glucose control in individuals with T1D using sensor-augmented insulin pump (SAP) therapy.

One week of GoCARB use was compared with conventional methods to estimate meal CHO content in 20 adults with T1D using SAP therapy (mean age 35 ± 14 years, BMI 25.5 ± 3.8 kg/m2, HbA1c 7.5 ± 0.6% [58.7 ± 5.9 mmol/mol], duration of diabetes 17 ± 10 years, …
Identifying Biomarkers in the Autoimmune Lymphoproliferative Syndrome (ALPS): IL-18, TNF-á, Serum Vitamin B12, Soluble FasL, and Plasma IL-10 Levels Are Useful Adjuvant Diagnostic Tools.
Authors: Iusta Caminha, Thomas Fleisher, Julie Niemela, Ron Hornung, Joie Davis, Katie Perkins, Kennichi Dowdell, Susan Price, Margaret Brown, V. Koneti Rao, Joao Bosco Oliveira
Journal: Blood (2009)
Do farm-grown lungs breathe better?
Authors: Jon Genuneit, Erika von Mutius
Journal: Thorax (2016)

In Thorax , Campbell et al 1 report an association of growing up on a farm with better adult lung function. On closer investigation, this effect was confined to the FEV1 in female participants in the study. A novel finding and a paper worth reading—but what may be harder to glean is its relevance and implication for future research.

The ‘farm-effect’ on allergic disease has been well established in numerous studies. Recent systematic reviews with meta-analyses show a strong protective effect of growing up on a farm on childhood atopy2 and a lesser effect on childhood asthma.3 In these meta-analyses, the effect estimates for the ‘farm-effect’ on asthma were much more heterogeneous than those on any atopic sensitisation.2 ,3 This may be driven by the mix of different farm exposures shown to be important.4 It has also been suggested that the increased heterogeneity in estimates of the ‘farm-effect’ on asthma is partly driven by the mix of asthma phenotypes in the respective studies.3

Indeed, the present study by Campbell et al is one of the few studies presenting results completely stratified by atopy to investigate this further. Here, the authors conclude that protective effects on atopic asthma, atopic bronchial hyper-responsiveness (BHR) and atopic nasal symptoms in comparison to non-atopic subjects without asthma, BHR and nasal symptoms, respectively, exist. On closer investigation of the presented data, these associations are fully driven by the ‘farm effect’ on atopy. No separate ‘farm-effect’ on asthma, BHR or nasal symptoms shows …
Transfusion Requirement, Spleen Size and Donor Type Are Strong Predictors of Outcome in Patients with Primary Myelofibrosis Undergoing an Allogeneic Stem Cell Transplant
Authors: Andrea P Bacigalupo, Alida Dominietto, Sarah Pozzi, Simona Geroldi, Maria Teresa van Lint, Anna Maria Raiola, Giovanni Barosi
Journal: Blood (2012)
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment.
Authors: Michele Cea, Antonia Cagnetta, Gabriella Cirmena, Anna Garuti, Ilaria Rocco, Claudia Palermo, Ivana Pierri, Marco Gobbi, Alberto Ballestrero, Alessio Nencioni, Franco Patrone, Angelo Michele Carella
Journal: Blood (2010)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Authors: Michael Boyiadzis, Michael R. Bishop, Rafat Abonour, Kenneth C. Anderson, Stephen M. Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen Van Besien, P. Leif Bergsagel, Ivan Borrello, Joshua Brody, Jill Brufsky, Mitchell Cairo, Ajai Chari, Adam Cohen, Jorge Cortes, Stephen J. Forman, Jonathan W. Friedberg, Ephraim J. Fuchs, Steven D. Gore, Sundar Jagannath, Brad S. Kahl, Justin Kline, James N. Kochenderfer, Larry W. Kwak, Ronald Levy, Marcos de Lima, Mark R. Litzow, Anuj Mahindra, Jeffrey Miller, Nikhil C. Munshi, Robert Z. Orlowski, John M. Pagel, David L. Porter, Stephen J. Russell, Karl Schwartz, Margaret A. Shipp, David Siegel, Richard M. Stone, Martin S. Tallman, John M. Timmerman, Frits Van Rhee, Edmund K. Waller, Ann Welsh, Michael Werner, Peter H. Wiernik, Madhav V. Dhodapkar
Journal: Journal for ImmunoTherapy of Cancer (2016)

Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.
Achieving the potential of colonoscopy screening
Authors: Roland Valori
Journal: Endoscopy (2016)

There is now strong evidence that lower bowel endoscopy can prevent colorectal cancer (CRC) and good evidence that the strength of this effect depends on the quality of the procedure [1] [2] [3]. Two studies have demonstrated that adenoma detection rate (ADR) predicts interval cancer [2] [3]. One of these studies demonstrated a reduction in death from CRC in patients screened by colonoscopists who were high adenoma detectors compared with patients screened by low detectors [3]. High quality colonoscopy is critical to the effectiveness of CRC screening.
Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing – an NCI/COG Target AML Study
Authors: Soheil Meshinchi, Rhonda E. Ries, Lisa R. Trevino, Oliver A. Hampton, Todd Alonzo, Jason E. Farrar, Jaime M. Guidry Auvil, Tanja M. Davidsen, Patee Gesuwan, Donna M. Muzny, Alan S. Gamis, Heather L. Helton, David A. Wheeler, Malcolm A. Smith, Daniela S. Gerhard, Robert J. Arceci
Journal: Blood (2012)
Pre-Autologous Stem Cell Transplantation (ASCT) Treatment with Rituximab Does Not Impair Stem Cell Harvest and Engraftment in Untreated Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.
Authors: Barbara Botto, Umberto Vitolo, Sergio Cortelazzo, Annalisa Chiappella, Bernardino Allione, Emanuele Angelucci, Carola Boccomini, Maria Giuseppina Cabras, Manuela Ceccarelli, Giovannino Ciccone, Francesco Di Vito, Lorenzo Falchi, Attilio Guarini, Anna Marina Liberati, Patrizia Pregno, Andrea Rossi, Giuseppe Rossi, Delia Rota Scalabrini, Alessandra Tucci, Tiziano Barbui, Eugenio Gallo
Journal: Blood (2005)
How Best to Express the Results of Serial RQ-PCR Studies to Measure Minimal Residual Disease in Treated Leukaemia Patients?.
Authors: Mona Anand, Jaspal S. Kaeda, Richard Szydlo, Jamshid S. Khorshad, David Marin, Bryony Swale, Sue Saunders, Eduardo Olavarria, John M. Goldman, Jane F. Apperley
Journal: Blood (2004)
Human Myeloma Cells Undergo Differentiation and Apoptosis upon Exposure of Rosiglitazone and All-Trans Retinoic Acid Via Apoptosis Signaling Pathway Modulation
Authors: Haiwen Huang, Wu Depei, Guanghua Chen, Weirong Chang, Anska Y.H. Leung, Raymond Liang, Howard C.H. Chow
Journal: Blood (2008)
Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.
Authors: Nikoletta Lendvai, Sacha Gnjatic, Erika Ritter, Yao-Tseng Chen, Christina Coughlin, Robert H. Vonderheide, Ruben Niesvizky, Nina Bhardwaj, Selina Chen-Kiang, Lloyd J. Old, Hearn J. Cho
Journal: Blood (2006)
Regulation of Genes of the Circadian Clock In Human Chronic Myeloid Leukemia: Abolished Daily Oscillation of PER1, PER2, PER3 and CRY2.
Authors: Ming-Yu Yang, Wen-Chi Yang, Pai-Mei Lin, Jui-Feng Hsu, Hui-Hua Hsiao, Yi-Chang Liu, Hui-Jen Tsai, Chao-Sung Chang, Sheng-Fung Lin
Journal: Blood (2010)
IL-35 and Rapamycin Reduce Acute Graft-Versus-Host Disease Associated with Decreased Platelet Aggregation in a Mouse Model
Authors: Xiao-Hui Zhang, Yi Zhou, Shi-yuan Zhou, Fei-er Feng, Qian-ming Wang, Wei Han, Huan Chen, Yu-hong Chen, Feng-rong Wang, Xiao Jun Huang
Journal: Blood (2014)
Oxidant Pathway Functional Polymorphisms Influence the Risk of Myeloid Leukemia/Transient Myeloproliferative Disorder In Children with Down Syndrome.
Authors: Jennifer M. Pope, Mi-Ok Kim, Todd A. Alonzo, Robert B. Gerbing, Melissa Rayburg, Gretchen Radloff, Alan S. Gamis, Stella M. Davies, John Perentesis
Journal: Blood (2010)
Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograft Murine Model
Authors: Weiguo Zhang, Charlie Ly, Qi Zhang, Hong Mu, Venkata Lokesh Battula, Nalini Patel, Wendy Schober, Xin Han, William E. Fogler, John L Magnani, Michael Andreeff
Journal: Blood (2016)
Monocentric survey about the use of Raltitrexed in the daily clinical practice for patients with metastatic colorectal cancer
Authors: A. Ponzetti, G.M. Zaccaria, S. Bustreo, C. Mecca, R. Spadi, L. Fanchini, G. Ritorto, M. Zanini, L. Ciuffreda, P. Racca
Journal: Annals of Oncology (2016)
β-alanine efficacy for sports performance improvement: from science to practice
Authors: George P Nassis, Ben Sporer, Christos G Stathis
Journal: British Journal of Sports Medicine (2016)

β-alanine is a popular supplement among athletes with 61% of competitive team sport players recently surveyed reporting β-alanine use.1 Despite its popularity, there is limited evidence on the most effective supplementation strategy and the systematic review and meta-analysis published by Sauders B et al 2 has shed some light on this issue. Athletes' understanding of β-alanine potential benefits and appropriate daily dose and duration of consumption is low,1 potentially compromising the impact of β-alanine supplementation in a real world setting. This editorial aims to highlight issues regarding the efficacy of β-alanine supplementation and suggest possible approaches to improve its effectiveness in the field.

The mechanism of ergogenic effect of β-alanine as the precursor to carnosine synthesis is associated with an expansion of its key physiological role as a proton buffer with potential for antioxidant, glycation and calcium regulation influence.3 Increases in carnosine muscle levels depend on the β-alanine load provided.4 β-alanine supplementation of 4–6 g/day for …
Transcutaneous Immunization with a Solid Nanoscopic Imiquimod Suspension Enhances Tumor Rejection
Authors: Pamela Stein, Karsten Gogoll, Tanja Peters, Mark Denny, Stefan Tenzer, Stefan Stevanovic, Hansjoerg Schild, Matthias Theobald, Peter Langguth, Markus Radsak
Journal: Blood (2015)
Association Between Pandemic Influenza A(H1N1) Vaccination in Pregnancy and Early Childhood Morbidity in Offspring
Authors: Anders Hviid, Henrik Svanström, Ditte Mølgaard-Nielsen, Philipp Lambach
Journal: JAMA Pediatrics (2016)

Several studies investigating potential adverse effects of the pandemic A(H1N1) vaccine have supported that influenza A(H1N1) vaccination does not increase the risk for major pregnancy and birth adverse outcomes, but little is known about possible adverse effects in offspring of A(H1N1)-vaccinated mothers beyond the perinatal period and into early childhood.To evaluate whether pandemic influenza A(H1N1) vaccination in pregnancy increases the risk for early childhood morbidity in offspring.Register-based cohort study comprising all live-born singleton children in Denmark from pregnancies overlapping the A(H1N1) influenza vaccination campaign in Denmark, from November 2, 2009, to March 31, 2010. From a cohort of 61 359 pregnancies, offspring exposed and unexposed to the influenza A(H1N1) vaccine during pregnancy were matched 1:4 on propensity scores.Vaccination in pregnancy with a monovalent inactivated AS03-adjuvanted split virion influenza A(H1N1)pdm09 vaccine (Pandemrix; GlaxoSmithKline Biologicals).Rate ratios of hospitalization in early childhood until 5 years of age. Hospitalization was defined as (1) first inpatient hospital admission, (2) all inpatient hospital admissions, and (3) first hospital contact for selected diseases, which included individual infectious diseases and individual neurologic, autoimmune, and behavioral conditions.The mean (SD) age at end of follow-up was 4.6 (0.40) years for the 61 359 children included in the study. In the cohort, the mothers of 55 048 children were unvaccinated, 349 mothers were vaccinated in the first trimester, and 5962 mothers were vaccinated in the second or third trimesters. Children exposed in the first trimester were not more likely to be hospitalized in early childhood than unexposed children (hospitalization rates per 1000 person-years, 300.6 for exposed vs 257.5 for unexposed; rate ratio, 1.17; 95% CI, 0.94-1.45). Similarly, children exposed in the second or third trimester were not more likely to be hospitalized in early childhood than unexposed children (hospitalization rates per 1000 person-years, 203.6 for exposed vs 219.3 for unexposed; rate ratio, 0.93; 95% CI, 0.87-0.99). This 7% decreased risk was primarily a result of reduced risks for infectious disease-related hospitalizations.To our knowledge, this is the most comprehensive study to date of potential adverse effects manifesting after the perinatal period. We detected no increased risk for early childhood morbidity. These results support the safety profile of the influenza A(H1N1) vaccine used in pregnancy.
Phase I Study of a New Humanized Anti-CD20 Monoclonal Antibody (LY2469298) in Japanese Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL) Pretreated with Rituximab-Containing Regimen
Authors: Michinori Ogura, Kensei Tobinai, Toshiki Uchida, Yukio Kobayashi, Takashi Oyama, Takashi Watanabe, Tatsuya Suzuki, Dai Maruyama, Masanobu Kasai, Masakazu Mori, Tomomi Matsue, Damien Cronier, James E Wooldridge, Minori Koshiji
Journal: Blood (2010)
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease Following Bone Marrow Transplantation,
Authors: Lucrezia Colonna, Mareike Florek, Dennis B Leveson-Gower, Emanuela I Sega, Robert Zeiser, Martin Buess, Robert S Negrin
Journal: Blood (2011)
Genetic Evolution of Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) during Therapy and Relapse: An Exome Sequencing Study of 47 Cases
Authors: Luise Hartmann, Sebastian Vosberg, Klaus H. Metzeler, Daniela Schumacher, Friederike Pastore, Kathrin Bräundl, Evelyn Zellmeier, Bianka Ksienzyk, Nikola P Konstandin, Stephanie Schneider, Alexander Graf, Helmut Blum, Martin Neumann, Claudia D Baldus, Stefan K Bohlander, Stephan Wolf, Stefan Wiemann, Wolfgang Hiddemann, Karsten Spiekermann, Philipp A Greif
Journal: Blood (2014)
Sarcopenia Determined by Computed Tomography (CT) imaging is a Better Prognosis Factor Than Albuminemia or Charlson Index in Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL),
Authors: Jerome Kraut, Romain Modzelewski, Helene Lanic, Mickael Loschi, Marion Alcantara, Jean-Michel Picquenot, Stéphane Leprêtre, Emile Lemasle, Aspasia Stamatoullas, Herve Tilly, Fabrice Jardin
Journal: Blood (2011)
Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) after Frontline Therapy with Hyper-CVAD Regimens.
Authors: Deborah A. Thomas, Susan O’Brien, Michael Rytting, Stefan Faderl, Jorge Cortes, William G. Wierda, Farhad Ravandi, Hagop M Kantarjian
Journal: Blood (2008)
Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia: Role of the NPM1 Mutations May Be Different in Different Races.
Authors: Yunsuk Choi, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim, Sung-nam Lim, Sung-Doo Kim, Miee Seol, Eul-Ju Seo, Seo-Jin Park, Seongsoo Jang, Chan Jeoung Park, Hyun Sook Chi, Kyoo-Hyung Lee
Journal: Blood (2009)
Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients
Authors: Neha Korde, Qing Yan Liu, Mary Kwok, Elisabet E. Manasanch, Olga Simakova, Sham Mailankody, Mark Roschewski, Adriana Zingone, Rene Costello, Diamond Zuchlinski, Marcia Mulquin, Katherine R Calvo, Raul C. Braylan, Irina Maric, Ola Landgren
Journal: Blood (2012)
Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies
Authors: Shaji Kumar, Joseph R. Mikhael, Betsy R. LaPlant, Joseph P. Colgan, David James Inwards, Patrick B. Johnston, Kristina Laumann, Ivana N. Micallef, Grzegorz S. Nowakowski, Stephen M. Ansell, Kelly Curtis, Angela Dispenzieri, Martha Q Lacy, Jose F. Leis, Donald Northfelt, Craig B. Reeder, James L. Slack, Thomas E. Witzig
Journal: Blood (2011)
Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway.
Authors: Hiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, Enrique M. Ocio, Tanyel Kiziltepe, Sonia Vallet, Yutaka Okawa, Shweta Chhetri, Kumar Sukhdeo, Kenji Ishitsuka, Klaus Podar, Noopur Raje, Dharminder Chauhan, Daniel R. Cattasco, Kenneth C. Anderson
Journal: Blood (2006)
Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study
Authors: Timothy P. Hughes, Marco Aurelio Salvino, Ong Tee Chuan, Alaa Elhaddad, Kudrat Abdulkadyrov, Jake Shortt, Hang Quach, Carolina Pavlovsky, Vernon J. Louw, Lee-Yung Shih, Anna G. Turkina, Luis Meillon, Yu Jin, Sadhvi Khanna, Darshan Dalal, Jeffrey H. Lipton
Journal: Blood (2015)
hERG Channels: From Antitargets to Novel Targets for Cancer Therapy
Authors: Annarosa Arcangeli, Andrea Becchetti
Journal: Clinical Cancer Research (2016)

Abstract In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K+ channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to fatal arrhythmias in humans. Clin Cancer Res; 23(1); 3–5. ©2016 AACR. See related article by Pointer et al., p. 73
Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using Alemtuzumab and Cyclophosphamide as Conditioning Regimen.
Authors: Fernanda Lodi, Gustavo Teixeira, Antonio Vaz Macedo, Rosana Lamego, Simone Silva Magalhaes, Ana Flavia Tiburcio, Ana Luiza Santoro, Rodrigo Gomes, Ana Karine Vieira, Sandra Xavier, Henrique Bittencourt
Journal: Blood (2009)
Assessing Incidence of and Risk Predictors Ascertained at Diagnosis for Symptomatic Venous Thrombotic Events in Pediatric Cancer Patients: A 20-Year Population Based Study from the Maritimes, Canada
Authors: Zeina Asyyed, Tamara MacDonald, Victoria E. Price, Conrad Fernandez, Mark Bernstein, Ketan Kulkarni
Journal: Blood (2015)